Schwartz Investment Counsel Inc. boosted its stake in Medtronic PLC (NYSE:MDT) by 1.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 533,907 shares of the medical technology company’s stock after buying an additional 10,000 shares during the period. Medtronic accounts for approximately 2.6% of Schwartz Investment Counsel Inc.’s portfolio, making the stock its 9th largest position. Schwartz Investment Counsel Inc.’s holdings in Medtronic were worth $41,522,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Captrust Financial Advisors bought a new position in shares of Medtronic during the second quarter valued at approximately $384,000. Wesbanco Bank Inc. increased its stake in shares of Medtronic by 3.1% during the second quarter. Wesbanco Bank Inc. now owns 10,170 shares of the medical technology company’s stock valued at $903,000 after purchasing an additional 308 shares in the last quarter. Dupont Capital Management Corp increased its stake in shares of Medtronic by 28.8% during the second quarter. Dupont Capital Management Corp now owns 74,052 shares of the medical technology company’s stock valued at $6,572,000 after purchasing an additional 16,562 shares in the last quarter. Chilton Investment Co. LLC increased its stake in shares of Medtronic by 6.1% during the second quarter. Chilton Investment Co. LLC now owns 26,842 shares of the medical technology company’s stock valued at $2,382,000 after purchasing an additional 1,538 shares in the last quarter. Finally, Moors & Cabot Inc. increased its stake in shares of Medtronic by 0.4% during the second quarter. Moors & Cabot Inc. now owns 43,227 shares of the medical technology company’s stock valued at $3,842,000 after purchasing an additional 178 shares in the last quarter. Institutional investors and hedge funds own 81.85% of the company’s stock.

Shares of Medtronic PLC (NYSE:MDT) traded up $0.50 on Friday, hitting $81.07. 4,072,036 shares of the company traded hands, compared to its average volume of 5,429,112. The company has a market capitalization of $109,728.09, a P/E ratio of 17.47, a P/E/G ratio of 2.24 and a beta of 1.00. The company has a quick ratio of 2.05, a current ratio of 2.40 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 12 month low of $69.35 and a 12 month high of $89.72.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.08. The company had revenue of $7.05 billion during the quarter, compared to the consensus estimate of $7.05 billion. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.12 earnings per share. equities analysts predict that Medtronic PLC will post 4.77 earnings per share for the current fiscal year.

In other Medtronic news, CEO Omar Ishrak sold 140,407 shares of Medtronic stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $81.63, for a total value of $11,461,423.41. Following the completion of the sale, the chief executive officer now owns 668,503 shares of the company’s stock, valued at approximately $54,569,899.89. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Bryan C. Hanson sold 16,000 shares of Medtronic stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $78.03, for a total transaction of $1,248,480.00. The disclosure for this sale can be found here. Insiders have sold 172,407 shares of company stock valued at $13,974,223 in the last three months. 0.31% of the stock is owned by insiders.

A number of equities analysts have weighed in on the stock. Cowen set a $95.00 target price on shares of Medtronic and gave the company a “buy” rating in a research note on Tuesday, August 22nd. Oppenheimer reaffirmed a “buy” rating and set a $92.00 target price on shares of Medtronic in a research note on Tuesday, August 22nd. Royal Bank Of Canada reaffirmed a “buy” rating and set a $90.00 target price on shares of Medtronic in a research note on Monday, August 21st. Stifel Nicolaus raised their target price on shares of Medtronic from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Wednesday, November 22nd. Finally, Northland Securities reaffirmed a “hold” rating and set a $80.00 target price on shares of Medtronic in a research note on Wednesday, November 22nd. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $88.02.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/10/medtronic-plc-mdt-shares-bought-by-schwartz-investment-counsel-inc.html.

Medtronic Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.